Sun Pharmaceutical Industries Limited
SUNPHARMA
Peringkat dalam Saham
#526
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Harga Saham
$19.24
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$46.15B
Perubahan (1 hari)
-0.97%
Perubahan (1 tahun)
0.11%
Negara
IN
Perdagangan Sun Pharmaceutical Industries Limited (SUNPHARMA)
Kategori
Healthcare
Rasio P/E untuk Sun Pharmaceutical Industries Limited (SUNPHARMA)
Rasio P/E per October 2026 TTM: 34.96
Menurut laporan keuangan dan harga saham terbaru dari Sun Pharmaceutical Industries Limited, rasio P/E saat ini (TTM) adalah 34.96. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 40.82.
Riwayat rasio P/E untuk Sun Pharmaceutical Industries Limited dari 2004 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 34.96 | -6.12% |
| 2025 | 37.24 | -8.76% |
| 2024 | 40.82 | 46.64% |
| 2023 | 27.84 | -58.49% |
| 2022 | 67.06 | 35.77% |
| 2021 | 49.39 | 120.00% |
| 2020 | 22.45 | -47.91% |
| 2019 | 43.10 | -23.53% |
| 2018 | 56.37 | 137.38% |
| 2017 | 23.75 | -43.25% |
| 2016 | 41.84 | -22.87% |
| 2015 | 54.25 | 43.15% |
| 2014 | 37.89 | 34.09% |
| 2013 | 28.26 | 23.87% |
| 2012 | 22.81 | -9.59% |
| 2011 | 25.23 | -8.43% |
| 2010 | 27.55 | 124.78% |
| 2009 | 12.26 | -22.35% |
| 2008 | 15.79 | -33.19% |
| 2007 | 23.63 | -15.09% |
| 2006 | 27.83 | 28.76% |
| 2005 | 21.61 | 18.29% |
| 2004 | 18.27 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.